Save Studies Locally
We can save your selected studies locally in your browser to enhance your experience. This data stays on your device and is not shared with us or third parties. You can clear this data at any time.
By allowing this, you consent to storing study selections locally on your device. Privacy Policy
How to NavigateEcosystem ConnectDistinguished InvestigatorsGlobal ConferencesRLT EducationRLT ComponentsSponsorsTrial Stats
Phase I/IIa First-in-Human Study of [212Pb]VMT01 Targeted Alpha-Particle Therapy for MC1R Positive Advanced Malignant Melanoma Dose
Description:
In this first-in human, phase I/IIa study, the safety and efficacy of [212Pb]VMT01, an alpha-particle emitting therapeutic agent targeted to melanocortin sub-type 1 receptor (MC1R) is being evaluated in patients with unresectable and metastatic melanoma.
Sponsor:
Viewpoint Molecular Targeting
Contacts:
Markus Puhlmann, MDmpuhlmann@perspectivetherapeutics.com
319-665-2151
Government Study Link:
NCT05655312 - Click here to see study onClinicalTrials.gov
